FindTrial
Sign In

Efficacy of dapagliflozin versus liraglutide in overweight and obese patients with inadequately controlled type 2 diabetes with insulin therapy

Clinical observation of dapagliflozin versus liraglutide in overweight and obese patients with inadequately controlled type 2 diabetes with insulin therapy

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019864
Enrollment
Unknown
Registered
2018-12-02
Start date
2018-12-16
Completion date
Unknown
Last updated
2018-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

diabetes

Interventions

Group 1:Dapagliflozin
Group 2:Liraglutide

Sponsors

Tianjin Medical University Metabolic Diseases Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: BMI>24kg/m2 waist circumference(male>90 cm and female>85 cm), HbA1c=8%

Exclusion criteria

Exclusion criteria: (1) type 1 and other special diabetes mellitus, gestational diabetes mellitus or pregnancy with diabetes mellitus; (2) complicated with cerebral infarction or severe mental illness, unclear consciousness; (3) patients with infectious diseases such as active tuberculosis; (4) patients with severe cardiopulmonary function and hepatic and renal insufficiency.

Design outcomes

Primary

MeasureTime frame
HbA1c;weight;Visceral fat;waist circumference;Daily insulin dosage;—

Secondary

MeasureTime frame
Islet function;—

Countries

China

Contacts

Public ContactHuang Xiao

Tianjin Medical University Metabolic Diseases Hospital

huangxiao2682@163.com+86 13821565470

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026